Syngene International Limited — PPTs, 29-07-2026: Investor Presentation

Here's a concise, retail-friendly summary based on the investor presentation:

**1. Business Performance:**

Syngene's Q1 FY27 revenue from operations dropped 16% YoY to Rs 736 Cr. Operating EBITDA margin was 12% (down from 24% in Q1 FY26), and PAT (before exceptional items) stood at Rs 1 Cr. This was largely due to lower off-take from a key client and forex hedge losses, partly eased by cost-cutting efforts.

**2. Growth Drivers or Strategy:**

The company is advancing its three-pronged growth strategy: expanding integrated Discovery Services across various molecule types, boosting Large and Small Molecule CDMO capabilities, and leveraging Dedicated R&D Centers. Operational excellence and robust ESG practices remain key strategic pillars.

**3. Recent Developments:**

Siddharth Mittal is the new MD & CEO. Syngene partnered with BRIC-THSTI for clinical development and research. They also enhanced Syn.AI, their AI platform, for faster drug discovery via gigascale screening and AI-driven molecule design. The company was recognized among the "World's Most Sustainable Companies 2026."

**4. Key Financial Metrics:**

Q1 FY27 Revenue: Rs 736 Cr (-16% YoY). Operating EBITDA margin: 12%. PAT (before exceptional items): Rs 1 Cr.

**5. Management Commentary / Outlook:**

Management forecasts H1 FY27 degrowth but expects H2 momentum to improve. This should lead to single-digit revenue degrowth for the full year, with EBITDA margins in the mid-20s.